EGFR and neoplasm: In the same database of GEMINI, we also identified patients whose tumor did not have EGFR mutation or ALK fusion (non-EGFR/ALK) and received first-line chemoIO therapy for their metastatic LUAD (n = 267); mPFS was 6.5 months in PD-L1 negative group, 8.6 months in PD-L1 low group, and 12.8 months in the high group, respectively (Figure 2B).